Results 91 to 100 of about 16,883 (239)

Impact on weight of a Doravirine switch in people living with HIV

HIV Medicine, Volume 27, Issue 1, Page 136-145, January 2026.
Abstract Background and Objective Doravirine is among the first‐line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti‐integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we
Nina Garofoli, Philippe Flandre, Jean‐Paul Vincensini, Quentin Richier, Priscille Couture, Karine Lacombe, Gilles Pialoux, Jean‐Luc Meynard   +7 more
wiley   +1 more source

Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed

Open Forum Infectious Diseases
Background We aimed to determine the effectiveness of switching to bictegravir in maintaining an undetectable viral load (
I. Núñez, Y. Caro-Vega, C. MacDonald, J. Mosqueda-Gómez, Alicia Piñeirúa-Menéndez, Anthony A. Matthews   +5 more
semanticscholar   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3471-3481, December 2025.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons

EClinicalMedicine, 2018
Background: Studies increasingly suggest that the efficacy of certain dual antiretroviral therapy (ART) combinations is equal to triple ART. Increasing concerns among HIV-positive patients and physicians in Switzerland include ART cost and long-term ART ...
Natascha D. Diaco, Claudio Strickler, Stéphanie Giezendanner, Sebastian A. Wirz, Philip E. Tarr   +4 more
doaj   +1 more source

Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study [PDF]

, 2023
Agete Tadewos Hirigo, Daniel Yilma, Ayalew Astatkie, Zelalem Debebe   +3 more
openalex   +1 more source

Pediatric human immunodeficiency virus infection in the modern era: A systematic review of recent advances and their implications

Pediatric Investigation, Volume 9, Issue 4, Page 394-404, December 2025.
This review discusses how early antiretroviral therapy initiation, long‐acting therapies, and prevention of mother‐to‐child transmission contribute to improved pediatric human immunodeficiency virus outcomes. Despite these advances, treatment complications and challenges in transitioning to adult care remain major barriers to lifelong management ...
Klaudia Nowak, Krzysztof Łupina, Dominika Lorek, Aleksandra Jabłońska, Alicja Radomska, Tymon Choromański, Jakub Janczura   +6 more
wiley   +1 more source

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Open Forum Infectious Diseases
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according ...
T. Tiendrebeogo, Karen Malateste, Armel Poda, A. Minga, E. Messou, H. Chenal, Oliver Ezechi, D. Ekouevi, I. Ofotokun, A. Jaquet   +9 more
semanticscholar   +1 more source

Long‐term risk and predictors of high‐risk human papillomavirus persistence after thermal ablation amongst women living with HIV in West Africa

HIV Medicine, Volume 26, Issue 12, Page 1950-1962, December 2025.
Abstract Introduction Mounting evidence supports the use of thermal ablation in women positively screened with high‐risk Human Papillomaviruses (hrHPV) but limited data are available on the long‐term post‐treatment outcomes in women living with HIV (WLHIV).
Simon Boni, Pierre Debaudrap, Firmin N. Kabore, Evelyne Kasile‐Pooda, Armel Poda, Belarsi Ouattara, Eugene Messou, Brahima Doukoure, Antoine Jaquet, Apollinaire Horo, on behalf IeDEA West Africa Collaboration   +10 more
wiley   +1 more source

Spectrophotometric quantification of dolutegravir based on redox reaction with Fe3+/1,10-phenanthroline

Future Journal of Pharmaceutical Sciences, 2020
Background A simple and sensitive spectrophotometric method was developed for the quantitative measurement of dolutegravir in pure form and pharmaceutical formulation.
Swathi Naraparaju, Durai Ananda Kumar Thirumoorthy, Sunitha Gurrala, Asra Jabeen, Pani Kumar D. Anumolu   +4 more
doaj   +1 more source

Body weight changes in people with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania

AIDS (London)
Objectives: To analyze weight changes associated with dolutegravir- versus efavirenz-based antiretroviral therapy (ART) in people with HIV (PWH) in rural Tanzania, where undernutrition is prevalent.
M. Weisser, H. Mapesi, F. Vanobberghen, J. Okuma, Anna Eichenberger, H. Wilson, Daniel H Paris, A. V. Kalinjuma, E. Luoga, L. Wilson, T. R. Glass, F. Franzeck   +11 more
semanticscholar   +1 more source